This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
cancer: Archive
Bull of the Day: Cardinal Health (CAH)
by Bryan Hayes
This company serves nearly 90% of US hospitals and delivers more than 43,000 pharmaceutical shipments daily.
CAHPositive Net Change
cancer dividends earnings hospitals investing medical medical-devices oncology-screening pharmaceuticals smart-health
Bull of the Day: Cardinal Health (CAH)
by Bryan Hayes
This company serves nearly 90% of US hospitals and delivers more than 43,000 pharmaceutical shipments daily.
CAHPositive Net Change
cancer dividends earnings hospitals investing medical medical-devices oncology-screening pharmaceuticals smart-health
Is Gilead Sciences (GILD) a 'Buy' Ahead of Its Upcoming Earnings Announcement?
by Bryan Hayes
The company's market-leading HIV franchise has fueled top-line growth.
GILDPositive Net Change
biotechnology cancer cell-therapy earnings investing medical oncology-screening stock-performance
Silver Economy Boom: Investing in Healthcare's Aging Tailwinds
by Urmimala Biswas
An aging population is reshaping healthcare, with BSX, RMD, ABBV and AMGN positioned to benefit from rising senior care demand.
ABTNegative Net Change BSXNegative Net Change AMGNNegative Net Change MDTPositive Net Change RMDPositive Net Change ABBVPositive Net Change
biotechs cancer healthcare hospitals medical medical-devices pharmaceuticals
Will BMY's Oncology Collaborations Drive Its Next Growth Phase?
by Ekta Bagri
BMY boosts its oncology pipeline with a Janux deal on tumor-activated therapy, alongside encouraging pumitamig data and multiple cancer collaborations.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change BNTXNegative Net Change
biotechnology biotechs cancer medical pharmaceuticals
3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment
by Kinjel Shah
J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.
JNJPositive Net Change PFENegative Net Change MRKNegative Net Change LLYNegative Net Change ABBVPositive Net Change FHTXPositive Net Change IBRXPositive Net Change
cancer pharmaceuticals
3 Cancer-Focused Stocks Showing Strong Pipeline Progress
by Kinjel Shah
Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.
PFENegative Net Change MRKNegative Net Change LLYNegative Net Change ABBVPositive Net Change FATEPositive Net Change VSTMPositive Net Change RLAYNegative Net Change
cancer pharmaceuticals
MRK vs. BMY: Which Pharma Stock Is the Smarter Pick Now?
by Ekta Bagri
Merck and Bristol Myers face diverging growth paths, with Keytruda driving MRK's momentum and BMY navigating generic headwinds.
BMYNegative Net Change MRKNegative Net Change
biotechnology biotechs cancer medical pharmaceuticals
Investing in Oncology: 3 Cancer Stocks With Promising Pipelines
by Kinjel Shah
Relay Therapeutics, Pyxis Oncology and Allogene Therapeutics drive cancer innovation with pivotal trials and promising drug candidates.
BMYNegative Net Change PFENegative Net Change LLYNegative Net Change ABBVPositive Net Change ALLONegative Net Change RLAYNegative Net Change PYXSNo Net Change
cancer pharmaceuticals
Merck Q2 Earnings in the Cards: Buy, Sell or Hold Ahead of Results?
by Kinjel Shah
MRK is gearing up to report Q2 earnings. While Keytruda drives growth, there are concerns over Gardasil's China sales, generics and pipeline depth.
AZNNegative Net Change MRKNegative Net Change SMMTNegative Net Change
cancer pharmaceuticals